The global AI In Life science Analytics Market is projected to be valued at USD 1.9 billion in 2024 and reach USD 3.6 billion by 2030, growing at a CAGR of 10.9% according to a new report by The ...

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights ...

Palvella Therapeutics Inc. Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the ...

The Company reported a net loss of approximately $6.4 million, or $0.13 per share, for the three months ended March 31, 2025, ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...

CLEVELAND, May 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results and business highlights for the first quarter of 2025 and shared recent operational ...

Quip Corporation, a leading AI-powered equipment rental and SaaS platform, today announced the acquisition of Rentz Corp, owner of rentmyequipment.com, a leading peer-to-peer equipment rental ...

Operator: Greetings, and welcome to the Kamada First Quarter 2025 Earnings Conference Call. At this time, all participants ...

Phase 3 SELVA trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 pa ...